Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatology Other
    Blood Flow Cytometry May Be Preferable Way to Diagnose, Analyse Mycosis Fungoides: Presented at ASCP - (DGDispatch)
    Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
    Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
    Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)
    Mycophenolate Mofetil Benefits Patients With Pemphigus Vulgaris: Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Dermatology Other
      Adverse Cutaneous Reactions Induced by TNF-[alpha] Antagonist Therapy
      Advancements in Enzymatic Debridement: Applying Clinical Science to Everyday Applications
      The Prevention and Treatment of Pressure Ulcers
      Contemporary Options for the Management of Scars
      Pediatric and Adolescent Sports-Related Injuries and Ailments

      Webcasts/CME archive

       Recent cases - Dermatology Other
        Something Fishy
        Russell Bodies in a Skin Biopsy: A Case Report
        Yellow Nail Syndrome
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)

        Cases archive
          




        my personal edition > dermatology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Fast Onset of Action Using Rupatadine 10 and 20 mg for Pruritis Relief in Patients With Chronic Urticaria: Presented at EADV

        By Chris Berrie

        VIENNA, AUSTRIA -- May 24, 2007 -- The potent new nonsedative antihistamine rupatadine provides rapid and long-lasting relief from pruritis in patients with moderate to severe chronic urticaria or chronic idiopathic urticaria (CIU), according to a combined analysis of pooled data from 2 multicentre, randomised, double-blind, placebo-controlled studies.

        Principal Investigator Ana Giménez-Arnau, MD, professor in dermatology, department of dermatology, Hospital del Mar, Barcelona, Spain, presented the results here on May 19th at the 16th European Academy of Dermatology and Venereology Congress (EADV).

        The structure of rupatadine fumarate conveys dual antagonistic properties upon this novel agent: as a potent selective antagonist towards the histamine H1 receptor, and as an antagonist towards platelet-activating factor receptors.

        As such, it has been shown to rapidly attenuate the symptoms of moderate to severe allergic rhinitis. Two randomised clinical trials in patients with CIU also demonstrated significant rapid and potent reduction in the severity of pruritis, in the number of wheals, and in the total symptom scores.

        Dr. Giménez-Arnau presented this pooled analysis that was aimed at determining the onset of pruritis relief following first daily oral dosing with the standard regimen of 10 mg or 20 mg rupatadine, for patients with moderate to severe chronic urticaria due to CIU or with no identifiable aetiology.

        The primary outcome efficacy determinations were mean variation of mean pruritis severity (MPS) scores from baseline over the 4 weeks of treatment with rupatadine. The researchers also monitored the mean variation in the number of wheals (MNW) and in total symptom score (MTSS).

        In the phase 2 trial, 283 patients were randomised to placebo or rupatadine at 5 mg, 10 mg, or 20 mg. In the phase 3 trial, 334 patients were randomised to placebo or to rupatadine at 10 mg or 20 mg.

        The demographics of the full pooled dataset were similar across these 4 patient-dosing groups of placebo (n = 182) and 5 mg (n = 70), 10 mg (n = 186), and 20 mg (n = 179) rupatadine dosing. The pooled analysis specifically considered placebo dosing versus both 10 mg and 20 mg rupatadine, Dr. Giménez-Arnau indicated.

        During each trial, patients were assessed following the first morning dosing at both 12 hours (first evening scoring) and 24 hours (first morning scoring).

        For the MPS scores, there were significantly greater reductions seen over placebo for rupatadine both at 10 mg (P <.01 for both) and 20 mg (P <.001 for both). Thus, at both doses, rupatadine effectively relieved the pruritis symptoms after the first 12-hour dosing.

        Similar significance and rapidity of onset was seen at both 12 and 24 hours from initial dosing for the MNW reductions (respectively) for placebo (11.0%, 21.5%) and for rupatadine at 10 mg (26.0%, 32.5%) and 20 mg (31.3%, 37.6%).

        Mean total symptoms scores at 12 and 24 hours according to MTSS reductions for the 3 dosing arms were 17.7%, 24.7% versus 31.9%, 36.8% versus 36.6%, 42.7%, respectively.

        Further analysis of the combined data for the MPS over the first full week of treatment demonstrated the continuing significant improvements in MPS scores over baseline relative to placebo for both rupatadine doses studied. After the initial rapid onset of pruritis relief, there was a further slow increase until day 7, when the maximal activity was seen at with the rupatadine 20-mg dose (P <.001 vs placebo). This was paralleled by the MNW and MTSS scores.

        "In conclusion, we can say that this new molecule is another new and effective antihistaminic, and just 10 or 20 mg are needed to provide rapid and long-lasting relief from pruritis, which is probably the most bothersome and troublesome symptom of chronic idiopathic urticaria," Dr. Giménez-Arnau said.

        This study was supported by Uriach Pharma.

        [Presentation title: Fast Onset of Action Using Rupatadine 10 and 20 mg for Pruritis Relief in Patients With Chronic Urticaria. Abstract FC10.7]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send